Viagra's Phase IV Problems
Executive Summary
Shattering all previous barriers for impotence, sales of {Viagra} soared to nearly $100 million its first month out. Most industry analysts and drug company executives expect {Viagra} will be a blockbuster for many years to come, but there is a contrarian view. Contrarians argue that signs of problems are already beginning to emerge.
You may also be interested in...
Lilly Icos: A Complementary Alliance
The Lilly Icos joint venture for the erectile dysfunction drug Cialis has the markings of a complementary alliance. Though too soon to gauge its commercial efficacy, so far the deal is working because both parties view it as a vehicle to build value of the sort important to them.
NHS England And Vertex Strike “Lightening Quick” CF Kaftrio/Trikafta Deal
An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.
Nine More Years? Sandoz Loses Again On Enbrel Biosimilar
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.
Need a specific report? 1000+ reports available
Buy Reports